No black box warning on record for Rifadin Iv

As of the latest FDA labeling reviewed, Rifadin Iv (RIFAMPIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rifadin Iv medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Hepatotoxicity of hepatocellular, cholestatic, and mixed patterns has been reported in patients treated with rifampin. Severity ranged from asymptomatic elevations in liver enzymes, isolated jaundice/hyperbilirubinemia, symptomatic self-limited hepatitis to fulminant liver failure and death. Severe hepatic dysfunction including fatalities were reported in patients with liver disease and i

No black box warning on record for Rifadin Iv

Other warnings & precautions

WARNINGS Hepatotoxicity of hepatocellular, cholestatic, and mixed patterns has been reported in patients treated with rifampin. Severity ranged from asymptomatic elevations in liver enzymes, isolated jaundice/hyperbilirubinemia, symptomatic self-limited hepatitis to fulminant liver failure and death. Severe hepatic dysfunction including fatalities were reported in patients with liver disease and i

Rifadin Iv Black Box Warning

No black box warning on record for Rifadin Iv

Other warnings & precautions

Rifadin Iv Black Box Warning

No black box warning on record for Rifadin Iv

Other warnings & precautions